|
[1]COTTER TG,RINELLA M.NAFLD 2020:The state of the disease[J].Gastroenterology,2020.[Online ahead of print]
|
|
[2]ADAMS LA,ROBERTS SK,STRASSER SI,et al.Nonalcoholic fatty liver disease burden:Australia,2019-2030[J].Gastroenterol Hepatol,2020.[Online ahead of print]
|
|
[3]JIANG YZ,NIE HM,WANG R.Pathogenesis of non-alcoholic fatty liver disease[J].J Clin Hepatol,2019,35(11):2588-2591.(in Chinese)姜煜资，聂红明，汪蓉．非酒精性脂肪性肝病的发病机制[J]．临床肝胆病杂志，2019,35(11):2588-2591．
|
|
[4]PACIFICO L,ANDREOLI GM,D'AVANZO M,et al.Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease[J].World J Gastroenterol,2018,24(19):2073-2082．
|
|
[5]LIU W,ZHANG X.Receptor activator of nuclear factor-κB ligand(RANKL)/RANK/osteoprotegerin system in bone and other tissues(review)[J].Mol Med Rep,2015,11(5):3212-3218．
|
|
[6]WONG BR,RHO J,ARRON J,et al.TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells[J].J Biol Chem,1997,272(40):25190-25194．
|
|
[7]LACEY DL,TIMMS E,TAN HL,et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J].Cell,1998,93(2):165-176．
|
|
[8]KARTSOGIANNIS V,ZHOU H,HORWOOD NJ,et al.Localization of RANKL(receptor activator of NF kappa B ligand)mRNA and protein in skeletal and extraskeletal tissues[J].Bone,1999,25(5):525-534．
|
|
[9]ANDERSON DM,MARASKOVSKY E,BILLINGSLEY WL,et al.Ahomologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function[J].Nature,1997,390(6656):175-179．
|
|
[10]DARNAY BG,HARIDAS V,NI J,et al.Characterization of the intracellular domain of receptor activator of NF-kappa B(RANK).Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase[J].J Biol Chem,1998,273(32):20551-20555．
|
|
[11]DARNAY BG,NI J,MOORE PA,et al.Activation of NF-kappa Bby RANK requires tumor necrosis factor receptor-associated factor(TRAF)6 and NF-kappa B-inducing kinase.Identification of a novel TRAF6 interaction motif[J].J Biol Chem,1999,274(12):7724-7731．
|
|
[12]HSU H,LACEY DL,DUNSTAN CR,et al.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J].Proc Natl Acad Sci U SA,1999,96(7):3540-3545．
|
|
[13]ONO T,HAYASHI M,SASAKI F,et al.RANKL biology:Bone metabolism,the immune system,and beyond[J].Inflamm Regen,2020,40:2．
|
|
[14]CHEN JY,WANG C,WANG J,et al.Research progress of MAPKsignal pathway[J].China Med Pharm,2011,1(8):42-44.(in Chinese)陈建勇，王聪，王娟，等．MAPK信号通路研究进展[J]．中国医药科学，2011,1(8):42-44．
|
|
[15]ZHANG B,LI M,ZOU Y,et al.Corrigendum:NF-κB/orai1 facilitates endoplasmic reticulum stress by oxidative stress in the pathogenesis of non-alcoholic fatty liver disease[J].Front Cell Dev Biol,2019,7:290．
|
|
[16]YANG L,WANG Z,JIANG L,et al.Total flavonoids extracted from oxytropis falcata bunge improve insulin resistance through regulation on the IKKβ/NF-κB inflammatory pathway[J].Evid Based Complement Alternat Med,2017,2017:2405124．
|
|
[17]KIL IS,KIM SY,PARK JW.Glutathionylation regulates Ikappa B[J].Biochem Biophys Res Commun,2008,373(1):169-173．
|
|
[18]WANG WQ,YI WC,LIN YH.Human umbilical cord mesenchymal stem cells alleviate liver damage of non-alcoholic fatty liver disease rats by inhibiting TLR4/NF-κB and oxidative stress[J/CD].Chin JCell Stem Cell(Electronic Edition),2018,8(5):297-302.(in Chinese)王文清，易文城，林拥华．脐带间充质干细胞介导TLR4/NF-κB炎症通路及氧化应激改善NAFLD大鼠肝脏损伤作用研究[J/CD]．中华细胞与干细胞杂志(电子版)，2018,8(5):297-302．
|
|
[19]KUMAR RAJENDRAN N,GEORGE BP,CHANDRAN R,et al.The Influence of Light on Reactive Oxygen Species and NF-кB in Disease Progression[J].Antioxidants(Basel),2019,8(12):640．
|
|
[20]MUSSO G,CASSADER M,GAMBINO R.Non-alcoholic steatohepatitis:Emerging molecular targets and therapeutic strategies[J].Nat Rev Drug Discov,2016,15(4):249-274．
|
|
[21]CHEN J,MONTAGNER A,TAN NS,et al.Insights into the Role of PPARβ/δin NAFLD[J].Int J Mol Sci,2018,19(7):1893．
|
|
[22]NEUSCHWANDER-TETRI BA.Therapeutic landscape for NAFLD in2020[J].Gastroenterology,2020,158(7):1984-1998.e3．
|
|
[23]EMERY JG,MCDONNELL P,BURKE MB,et al.Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL[J].J Biol Chem,1998,273(23):14363-14367．
|
|
[24]ZHANG C,LUO X,CHEN J,et al.Osteoprotegerin promotes liver steatosis by targeting the ERK-PPAR-γ-CD36 Pathway[J].Diabetes,2019,68(10):1902-1914．
|
|
[25]MARUYAMA K,TAKADA Y,RAY N,et al.Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice[J].J Immunol,2006,177(6):3799-3805．
|
|
[26]METRAKOS P,NILSSON T.Non-alcoholic fatty liver disease-a chronic disease of the 21~(st)century[J].J Biomed Res,2018,32(5):15-23．
|
|
[27]MANTOVANI A,SANI E,FASSIO A,et al.Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes[J].Diabetes Metab,2019,45(4):347-355．
|
|
[28]TAKENO A,YAMAMOTO M,NOTSU M,et al.Administration of anti-receptor activator of nuclear factor-kappa B ligand(RANKL)antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency:Acase report[J].BMC Endocr Disord,2016,16(1):66．
|
|
[29]HAO YL,BIAN ZL,JU LL,et al.RANK/RANKL acts as a protective factor by targeting cholangiocytes in primary biliary cholangitis[J].Dig Dis Sci,2020,65(2):470-479.
|
DownLoad: